Protagonist Therapeutics
PTGX
185 hedge funds and large institutions have $1.73B invested in Protagonist Therapeutics in 2024 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 61 increasing their positions, 57 reducing their positions, and 20 closing their positions.
145% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 20
29% more capital invested
Capital invested by funds: $1.34B → $1.73B (+$390M)
19% more funds holding
Funds holding: 156 → 185 (+29)
1.22% more ownership
Funds ownership: 101.69% → 102.91% (+1.2%)
7% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 57
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
83% less call options, than puts
Call options by funds: $1.14M | Put options by funds: $6.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$42.4M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$25.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$22.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$54.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.5M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$23.4M |
| 4 |
Morgan Stanley
New York
|
-$13.7M |
| 5 |
SC
Stempoint Capital
New York
|
-$11.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QL
201
Quarry LP
New York
| – | -$17.2K | -750 | Closed |
|
202
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2.29K | -100 | Closed |
|
203
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$115 | -5 | Closed |
|
|
C
204
Covestor
London,
United Kingdom
| – | -$27 | -1 | -20% |
|
|
GI
205
Gradient Investments
Arden Hills,
Minnesota
| – | -$23 | -1 | Closed |
|
PTGX Hedge Fund Activity: Q1 2024 in Review
185 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2024, worth a combined $1.73B — up 29% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new PTGX positions and 20 closed out — a net gain of 29 holders — while 61 added to existing stakes and 57 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $42.4M. The largest seller was BVF Inc, cutting an estimated $54.1M.
- 185 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2024, up from 156 in Q4 2023.
- Funds reported $1.73B of Protagonist Therapeutics stock for Q1 2024, up 29% quarter-over-quarter.
- 49 funds opened new Protagonist Therapeutics positions in Q1 2024 and 20 closed out, a net change of +29 holders.
- The largest Protagonist Therapeutics buyer in Q1 2024 was Cowen and Company, an estimated $42.4M added.
- The largest Protagonist Therapeutics seller in Q1 2024 was BVF Inc, an estimated $54.1M sold.
Based on aggregated 13F filings for Q1 2024.